title: Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
abstract: Hormonal therapy with either tamoxifen or aromatase inhibitors is commonly used to treat women with breast cancer in both the adjuvant and recurrent disease setting. Cutaneous adverse reactions to these drugs have been rarely reported in the literature. We report an unusual case of urticarial vasculitis following the aromatase inhibitor anastrozole that localised to the unilateral trunk and mastectomy scar, and review the literature on the cutaneous adverse effects of hormonal therapy for breast cancer.
authors.affiliation: Brien Walder Department of Dermatology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
authors.forename: Vanessa L
authors.initials: VL
authors.lastname: Bock
authors.forename: Michael
authors.initials: M
authors.lastname: Friedlander
authors.forename: Dale
authors.initials: D
authors.lastname: Waring
authors.forename: Steven
authors.initials: S
authors.lastname: Kossard
authors.forename: Glenda K
authors.initials: GK
authors.lastname: Wood
mesh_terms: D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006801:Humans; D009570:Nitriles / Q000009:adverse effects*; D014230:Triazoles / Q000009:adverse effects*; D014581:Urticaria / Q000139:chemically induced*; D014657:Vasculitis / Q000139:chemically induced*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole
keywords: adjuvant hormonal therapy; anastrozole; aromatase inhibitor; breast carcinoma; leukocytoclastic vasculitis; urticarial vasculitis